FCLFineotex Chemical Ltd.

    Fineotex Chemical Q2 FY27 Results: Consolidated Net Profit ₹44.55 Crore on Total Income of ₹391 Crore

    • Earnings
    • Speciality chemicals
    A chemical plant seen across a grassy field under a clear blue sky, with pipework, a white process building and rows of storage silos.
    Benoît Prieur, via Wikimedia Commons (CC0). Illustrative image.

    Fineotex Chemical (NSE: FCL) reported a consolidated total income of ₹391.41 crore and a consolidated net profit of ₹44.55 crore for the quarter ended 30 Sep 2026, it said in a filing on 13 Nov 2026. Standalone total income was ₹147.18 crore and standalone net profit ₹21.23 crore for the same quarter.

    Key highlights

    Consolidated

    Including its subsidiaries

    • Total income: ₹391.41 crore, up 169.2% YoY and 1.2% QoQ
    • Net profit and EPS: ₹44.55 crore, up 70.8% YoY and down 7.6% QoQ; basic EPS ₹0.38
    • Finance costs: ₹1.68 crore, against ₹0.34 crore a year earlier and ₹0.10 crore in Q1 FY27
    • Net profit attributable to owners: ₹34.24 crore, against ₹25.99 crore a year earlier

    Standalone

    The company on its own, without its subsidiaries

    • Total income: ₹147.18 crore, up 25.8% YoY and 53.4% QoQ
    • Net profit and EPS: ₹21.23 crore, down 15.8% YoY and up 3.4% QoQ; basic EPS ₹0.18
    • Other income: ₹9.56 crore, against ₹12.43 crore a year earlier

    Summary

    Consolidated ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    391.41145.43+169.2%386.72+1.2%
    44.5526.08+70.8%48.21-7.6%
    EPS, basic (₹)0.380.23+65.2%0.41-7.3%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Consolidated total income rose 169.2% year on year, while net profit rose 70.8%, so profit grew more slowly than income. Revenue from operations rose 181.5% to ₹387.65 crore, while other income fell 51.3% to ₹3.76 crore, which is 1.0% of total income this quarter.

    Profit before tax rose 61.1% to ₹57.02 crore and tax expense rose 33.9% to ₹12.48 crore, which is 21.9% of profit before tax. Net profit margin was 11.38% against 17.93% a year earlier.

    Finance costs were ₹1.68 crore against ₹0.34 crore a year earlier and ₹0.10 crore in Q1 FY27. The filing does not state the reason for the rise in finance costs or for the rise in revenue from operations.

    Quarter-on-quarter, consolidated total income rose 1.2% while net profit fell 7.6% and profit before tax fell 11.9%. Half-year figures in the filing show consolidated total income of ₹778.13 crore in the press highlights, and consolidated ROIC of about 36.12% and business volumes up about 132.30% for H1 FY27.

    Standalone ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    147.18116.98+25.8%95.93+53.4%
    21.2325.21-15.8%20.53+3.4%
    EPS, basic (₹)0.180.22-18.2%0.180.0%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Standalone total income rose 25.8% year on year to ₹147.18 crore, but net profit fell 15.8% to ₹21.23 crore. Revenue from operations rose 31.6% to ₹137.62 crore while other income fell 23.1% to ₹9.56 crore, which is 6.5% of total income.

    Profit before tax fell 16.6% to ₹27.79 crore, and tax expense fell 19.2% to ₹6.55 crore, which is 23.6% of profit before tax. Other income is 34.4% of profit before tax. Net profit margin was 14.43% against 21.55% a year earlier. Standalone net profit rose 3.4% quarter on quarter, against a 53.4% rise in total income.

    Standalone net profit is ₹21.23 crore, which is ₹23.32 crore lower than consolidated net profit of ₹44.55 crore.

    Inference

    The filing reports a corporate dividend paid of ₹5.82 crore standalone and ₹6.23 crore consolidated in the half year ended 30 Sep 2026.

    The filing says the legal dispute over the Assignment Agreement for property under Assets Held for Sale had not been settled as of 30 Sep 2026, and that the company has paid ₹6.25 crore towards its settlement. The nature and expected outcome of the dispute are not stated. The expected timing or amount of completion is not stated.

    The filing also says that during the quarter the company's step-down subsidiaries Fineotex Holdings Inc. and Fineotex America Inc. were incorporated through Fineotex Biotex Healthguard FZE. The statutory auditors issued unqualified limited review reports on both sets of results.

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Latest posts